Researchers have discovered that genetic changes accumulate more rapidly in MS brain lesions than in non-lesion tissue, with distinct patterns emerging in the lesions.
A pilot study has found an existing online cognitive behavioural therapy (CBT) program from Germany is highly acceptable to people with multiple sclerosis (MS) in Australia and achieved reduced levels of MS-related fatigue.
Phase 3 trials did not show a clear advantage of evobrutinib compared to current treatments for people with relapsing MS.
Luigi wanted his legacy to be one that made a difference. Through his generous bequest to MS Plus, he ensured that people living with multiple sclerosis would receive the support they need to live fuller, more independent lives.
The Federal Government has announced the listing of ravulizumab (Ultomiris®) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of adults with neuromyelitis optica spectrum disorders (NMOSD). This is a historic milestone as ravulizumab is the first-ever treatment specifically for NMOSD to be included on the PBS.
MS Australia is very pleased to see that health is the number one issue in this election, with solid commitments to reduce the costs of medicine and improve access to bulk billed services in general practice.
CEO Rohan Greenland has just registered for the May 50K for the fifth consecutive year and shares the many reasons why he really loves the event.
On International Women’s Day, we look at the disproportionate effects MS has on Australian women and the research MS Australia is supporting to address it.
A new multiple sclerosis (MS) research project designed to help the brain repair itself by activating its own healing processes has been announced as part of MS Australia’s latest $5.7 million research investment.
